- Manager, GMP Facility, Cell Processing Core
- Director, Human Islet Isolation, Cell Processing Core
Manager, Cellular Therapy & Transplant Core
Office: (434) 243-5452
University of Virginia
PO Box 801413
Charlottesville, VA 22908
450 Ray C. Hunt Drive
Aurbach Building, Room 2309
Charlottesville, VA 22903
About Linda Langman
Of the many projects Ms. Langman has been involved with in the Cellular Therapeutics & Transplant Core, she is most proud of the islet transplants made possible by the lab’s research. Referencing the work that the Core is doing with the Cell Processing Core and Induced Pluripotent Stem Cell Core, she states, “It is important progress in cell therapy to be able to use your own cells.” Ms. Langman was responsible for overseeing the creation of the Cell Processing Core – which follows strict FDA guidelines for Good Manufacturing Processes – and continues to maintain the Core and work on islet isolation for transplants. Ms. Langman also has projects examining the antibody immunoglobulin M, which has been shown to be a factor in how well a patient’s body tolerates a transplant.
Cell Isolation and Transplantation, IgM Therapy, 3D Bioprinting
- Islet Isolation Training, University of Miami
- Emergency Medical Technician Certification
- Medical Technologist, American Society of Clinical Pathologists
- B.S.M.T., James Madison University
- B.S., Biology, James Madison University
Moran I, Akerman I, Bunt M, Xie R, Benazra M, Nammo T, Arnes L, Nakic N, Garcıa-Hurtado J, Rodrıguez-Seguı S, Pasquali L, Sauty-Colace C, Beucher A, Scharfmann R, Arensbergen J, Johnson P, Berry A, Lee C, Harkins T, Gmyr V, Pattou F, Kerr-Conte J, Piemonti L, Berney T, Hanley N, Gloyn , Sussel L, Langman L, Brayman K, Sander M, McCarthy M, Ravassard P, Ferrer J. Human B Cell Transcriptome Analysis Uncovers IncRNAs That Are Tissue-Specific Dynamically Regulated, and Abnormally Expressed in Type 2 Diabetes. 2012; 435-448; Volume 16, Issue 3; Cell Metabolism.
Chhabra P, Wang K, Zeng Q, Jecmenica M, Langman L, Linden J, Ketchum RJ, Brayman KL. Adenosine A(2A) agonist administration improves islet transplant outcome: Evidence for the role of innate immunity in islet graft rejection. 2010;19(5):597-612. doi: 10.3727/096368910X491806; Cell Transplant. Epub 2010 Mar 26. PMID: 20350347
Yang Z, Chen M, Deng S, Ellett JD, Wu R, Langman L, Carter JD, Fialkow LB, Markmann J, Nadler JL, Brayman K. Assessment of human pancreatic islets after long distance transportation. 2004 Jun; 36(5); 1532-3. Transplant Proc. PMID: 15251378
Ketchum R, Langman L, Deng SP, et al. Successful transplantation of isolated pancreatic islets of langerhans from an ABO incompatible donor. 2007; Vol. 14, Iss.5; 474. Xenotransplantation.
Chhabra P, Zeng Q, Langman L, et al. Adenosine A2A receptor agonist ATL146e improves islet transplantation outcomes in mice. 2007; Vol. 15, Iss. 5; 519. Xenotransplantation.
Wang K, Langman L, Zhang N, et al. Recipient pre-treatment with adenosine A(2A) receptor agonist (ATL 146E) reduce islet dose requirement and time to normoglycemia in murine islet transplantation. 2005; Vol. 5; 312; Supplement: Suppl. 11; Meeting Abstract: 612. American Journal of Transplantation.